Geneva, Switzerland and Boston, MA – November 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
Geneva, Switzerland and Boston, MA – October 31, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity
J. Täubel, U. Lorch , G. Ferber , O Pohl
ACCP Conference, 17-19 September 2017, San Diego, CA
Poster 019: Page 16
ObsEva at Rodman & Renshaw Annual Global Investment Conference
Company Management will be presenting and holding one-on-one meetings with investors at Rodman & Renshaw 19th Annual Global Investment Conference. Date &…
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA – 11 September, 2017 – ObsEva SA (NASDAQ: OBSV),…
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
Geneva, Switzerland and Boston, MA – 06 September, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva at Baird Global Healthcare Conference
Company Management will be presenting and holding one-on-one meetings with investors at the Baird Global Healthcare Conference. Date & Time: 06 September…
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
Geneva, Switzerland and Boston, MA – 30 August, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…